肝细胞癌的癌变机制复杂，遗传因素可能在肝细胞恶性转化中发挥作用。已经对IL-10基因多态性进行了研究，以探索其在肝细胞癌中的潜在作用。本研究旨在通过对符合条件的个体研究进行荟萃分析，探究IL-10（-1082 A/G，-819 T/C，-592 A/C）与肝细胞癌之间的关系。本研究遵循PRISMA 2020清单。在相关的健康数据库中进行了相关研究的搜索。使用Newcastle-Ottawa Scale标准对研究质量进行评估。使用合并比值（OR）及其95％置信区间（CI）来确定每个多态性与肝细胞癌之间的关联强度，采用五种遗传模型进行分析。通过人种分层进行分析。通过进行试验序列分析（TSA）来确定所需信息大小。共鉴定了15个病例对照研究（n = 8182）。总体上，杂合子模型仅显示IL-10（-1082 A/G）与肝细胞癌风险之间存在微弱但显著的关联（OR：0.82，95％CI：0.67-1.00，9个研究）。在分层分析中，IL-10（-1082 A/G）与非亚洲人群中的肝细胞癌风险呈显著关联，包括显性（OR：0.62，95％CI：0.45-0.86，4个研究）、杂合子（OR：0.60，95％CI：0.43-0.85）和等位基因模型（OR：0.79，95％CI：0.64-0.99）。IL-10（-819 T/C）仅在非亚洲人群中与肝细胞癌风险显著关联，包括显性（OR：1.47，95％CI：1.02-2.13，8个研究）、隐性（OR：1.99，95％CI：1.03-3.86）和纯合子模型（OR：2.18，95％CI：1.13-4.23）。在11个研究中，IL-10（-592 A/C）与肝细胞癌在所有五种遗传模型中无显著关联（P值> 0.5）。TSA分析显示，对于IL-10（-592 A/C）分析的效应确凿性的信息大小已足够，但对于-1082 A/G和-819 T/C则不足够。研究发现暗示IL-10（-1082 A/G和-819 T/C）多态性与肝细胞癌存在种族特异性的关联。然而，由于样本量不足，这一证据并不确凿。IL-10（-592 A/C）多态性与肝细胞癌无关，尽管信息量足够充分。建议在不同人种中进行未来设计良好的大规模病例对照研究，以研究IL-10（-1082A / G和-819 T / C）。© 2023. BioMed Central Ltd., part of Springer Nature.

The carcinogenesis of hepatocellular carcinoma is complicated, and genetic factor may have the role in the malignant transformation of liver cells. IL-10 gene polymorphisms have been investigated for their potential roles in hepatocellular carcinoma This study aimed to investigate the relationship between polymorphisms of IL-10 (-1082 A/G, -819 T/C, -592 A/C), and hepatocellular carcinoma by performing a meta-analysis with eligible individual studies.This study followed the PRISMA 2020 Checklist. Relevant studies were searched in health-related databases. The Newcastle-Ottawa Scale criteria were used to evaluate the studies quality. Pooled odds ratio (OR) and its 95% confidence interval (CI) were used to determine the strength of association between each polymorphism and hepatocellular carcinoma using five genetic models. Stratification was done by ethnic groups. Trial sequential analysis (TSA) was performed to determine the required information size.Fifteen case-control studies (n = 8182) were identified. Overall, the heterozygous model showed a marginal significant association only between IL-10 (-1082 A/G) and hepatocellular carcinoma risk (OR: 0.82, 95% CI: 0.67-1.00, 9 studies). On stratification, IL-10 (-1082 A/G) was significantly associated with hepatocellular carcinoma risk in the non-Asian population under dominant (OR: 0.62, 95% CI: 0.45-0.86, 4 studies), heterozygous (OR: 0.60, 95% CI: 0.43-0.85) and allelic models (OR: 0.79, 95% CI: 0.64-0.99). IL-10 (-819 T/C) was significantly associated with hepatocellular carcinoma risk only among non-Asians under the dominant (OR: 1.47, 95% CI: 1.02-2.13, 8 studies), recessive (OR: 1.99, 95% CI: 1.03-3.86, and homozygous models (OR: 2.18, 95% CI: 1.13-4.23). For IL-10 (-592 A/C) with 11 studies, there was no significant association with hepatocellular carcinoma in all five genetic models (P values > 0.5). TSA plots indicated that the information size for firm evidence of effect was sufficient only for the analysis of IL-10 (-592 A/C), but not for the - 1082 A/G or -819 T/C.Findings suggest that IL-10 (-1082 A/G and - 819 T/C) polymorphisms are associated with hepatocellular carcinoma in ethnic-specific manner. However, this evidence is not conclusive because the sample size was insufficient. IL-10 (-592 A/C) polymorphism was not associated with hepatocellular carcinoma albeit with sufficient information size. Future well-designed large case-control studies on IL-10 (-1082 A/G and - 819 T/C) with different ethnicities are recommended.© 2023. BioMed Central Ltd., part of Springer Nature.